National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2016 (No. 2) (PB 14 of 2016) (Cth)

PB 14 of 2016

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2016 (No. 2)

National Health Act 1953
___________________________________________________________________________

I, Julianne Quaine, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.

Dated   26     February 2016           

JULIANNE QUAINE
Assistant Secretary
Pharmaceutical Access Branch
Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________

1              Name of Instrument

(1)This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2016 (No. 2).

(2)This Instrument may also be cited as PB 14 of 2016.

2             Commencement

This Instrument commences on 1 March 2016.

3              Amendments to PB 79 of 2011

Amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).

Amendments

1. Schedule 1 Part 1 entry for Doxorubicin – pegylated liposomal in each of the forms Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL; Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL and brand Liposomal Doxorubicin SUN:

   omit from the column headed ‘Responsible Person’: ZF  substitute: RA

2. Schedule 1 Part 1 entry for Gemcitabine in each of the forms Powder for I.V. infusion 200 mg (as hydrochloride); Powder for I.V. infusion 1 g (as hydrochloride) and brand Gemcitabine Sun:

   omit from the column headed ‘Responsible Person’: ZF  substitute: RA

3. Schedule 1 Part 1 entry for Oxaliplatin in each of the forms Solution concentrate for I.V. infusion 50 mg in 10 mL; Solution concentrate for I.V. infusion 100 mg in 20 mL; Solution concentrate for I.V. infusion 200 mg in 40 mL and brand Oxaliplatin SUN:

   omit from the column headed ‘Responsible Person’: ZF  substitute: RA

4. Schedule 1 Part 1 entry for Oxaliplatin in the form Solution concentrate for I.V.infusion 100 mg in 20 mL:

   omit:

Oxaliplatin MYX YN MP D

1. Schedule 2 entry for Folinic acid in the form Tablet containing calcium folinate equivalent to 15 mg folinic acid:

   Omit from the column headed ‘Circumstances’: C1028   substitute: C5973

2. Schedule 3 after entry for PL:

   insert:

 RA Ranbaxy Australia Pty Limited 17 110 871 826

1. Schedule 4 entry for Folinic acid:

   substitute:

Folinic acid C5973 P5973 Megaloblastic anaemias
The condition must be a result of folic acid deficiency from the use of folic acid antagonists.